-+ 0.00%
-+ 0.00%
-+ 0.00%

Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million

PUBT·04/30/2026 00:55:20
Listen to the news
Mesoblast posts Q3 Ryoncil net revenue of US$30.3 million
  • Mesoblast reported fiscal third-quarter net revenue from Ryoncil of US$30.3 million on gross sales of US$35.3 million.
  • Net operating cash spend narrowed to US$4.1 million, supported by receipts of US$34.6 million.
  • Cash on hand totaled US$122 million at March 31, 2026.
  • Patient recruitment target was reached in pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain.
  • Exclusive worldwide license was secured for patented CAR technology platform to develop precision-enhanced MSC products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604292055PRIMZONEFULLFEED9710140) on April 30, 2026, and is solely responsible for the information contained therein.